CHINA GEWANG BIOTECHNOLOGY, INC. AND SUBSIDIARIES - Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	May 31, 2016	May 31, 2015
Cash flows from operating activities:
Net income	$ 1,988,651	$ 708,917
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	24,761	13,915
(Income) from equity investment	(408,275)
Changes in operating assets and liabilities:
(Increase) in accounts receivable	(3,330,508)	(222,905)
Decrease (increase) in inventory	134,534	(46,444)
(Increase) in prepaid expenses	(1,346,283)	(35,401)
Increase (decrease) in accounts payable	1,235,947	(7,225)
(Decrease) in advances from customers		(56,930)
Increase in taxes payable	342,454	13,908
(Decrease) increase in accrued liabilities and other payables	(82,198)	75,053
Net cash (used in) provided by operating activities	(1,440,917)	442,888
Cash flows from investing activities:
Purchase of equipment	(78,677)	(24,550)
Net cash (used in) investing activities	(78,677)	(24,550)
Cash flows from financing activities:
Proceeds from stockholder loans		38,106
Proceeds from sale of common stock	9,848,200
Net cash provided by financing activities	9,848,200	38,106
Effect of exchange rate changes on cash	(306,441)	5,558
Net change in cash	8,022,165	462,002
Cash, Beginning of Period	8,669,034	3,012,812
Cash, End of Period	16,691,199	3,474,814
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest
Cash paid income taxes	264,032	229,218
Payable for purchase of equity investment	1,000,000
Additional paid-in capital - equity in excess of purchase price of investee under common control	466,652
Noncash financing activities:
Payment of accrued expenses and other payables by shareholder	$ 52,190	$ 40,797